Rapid decrease in rates of hospitalization resulting from invasive pneumococcal disease and community-acquired pneumonia in children aged < 60 months after 13-valent pneumococcal conjugate vaccine introduction in Argentina

Journal of the Pediatric Infectious Diseases Society

Volumn 7, Issue 1, 2018, Pages 30-35

  López, Eduardo L ^a   Glatstein, Eduardo ^b   Ezcurra, Gustavo C ^c   Iacono, Marisa ^d   Teplitz, Eduardo ^e   Garnero, Analía V ^b   Lazzarini, Daniela L ^a   Vázquez, Miryan ^a   Contrini, María M ^a  

^a HOSPITAL DE NIÑOS RICARDO GUTIÉRREZ   (Argentina)

^b Hospital de Ninos de la Santisima Trinidad   (Argentina)

^c 'O Alassia' Children's Hospital   (Argentina)

^d Hospital Provincial de Neuquén E Castro Rendón   (Argentina)

^e Hospital Privado Dr Raúl Matera   (Argentina)

Author keywords

Children; Invasive pneumococcal disease; Pneumococcal conjugate vaccine

Indexed keywords

PNEUMOCOCCUS VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ARGENTINA; ARTHRITIS; ARTICLE; BACTEREMIA; CELLULITIS; CHILD; COMMUNITY ACQUIRED PNEUMONIA; EMPYEMA; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MENINGITIS; MULTICENTER STUDY; PERITONITIS; PNEUMOCOCCAL INFECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; STREPTOCOCCUS PNEUMONIAE; VACCINATION; COMMUNITY ACQUIRED INFECTION; INFANT; MICROBIOLOGY; NEWBORN; PLEURA EMPYEMA; STATISTICS AND NUMERICAL DATA; STREPTOCOCCUS PNEUMONIA;

ARGENTINA; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; EMPYEMA, PLEURAL; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PNEUMOCOCCAL VACCINES; PNEUMONIA, PNEUMOCOCCAL;

EID: 85019218052     PISSN: 20487193     EISSN: 20487207     Source Type: Journal    
DOI: 10.1093/jpids/piw089     Document Type: Article

References (27)

1. Williams BG, Gouws E, Boschi-Pinto C, et al. Estimates of world-wide distribution of child deaths from acute respiratory infections. Lancet Infect Dis 2002; 2:25-32.
2. Bryce J, Boschi-Pinto C, Shibuya K, Black RE; WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005; 365:1147-52.
3. Worl Helath Organization. Pneumococcal conjugate vaccine for childhood immunization. Wkly Epidemiol Rec 2007; 82:93-104.
4. World Health Organization/United Nation Children's Fund (WHO/UNICEF). Global Immunization Vision and Strategy. Washington, DC: World Health Organization; 2005.
5. Ray GT, Whitney CG, Fireman BH, et al. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr Infect Dis J 2006; 25:494-501.
6. Centers for Disease Conrol and Prevention. Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb Mortal Wkly Rep. 2006; 55:511-15.
7. Tregnaghi M, Ceballos A, Rüttimann R, et al. Active epidemiologic surveillance of pneumonia and invasive pneumococcal disease in ambulatory and hospitalized infants in Cordoba, Argentina. Pediatr Infect Dis J 2006; 25:370-2.
8. Augustovski FA, García Martí S, Pichon-Riviere A, Debbag R. Childhood pneumococcal disease burden in Argentina. Rev Panam Salud Publica 2009; 25:423-30.
9. World Health Organization Pneumonia Vaccine Trial Investigators' Group. Standarization of Interpretation of Chest Radiographs for the Diagnosis of Pneumonia in Children. Geneva: World Health Organization; 2001.
10. Kaplan SL, Barson WJ, Lin PL, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J 2013; 32:203-7.
11. Ampofo K, Pavia AT, Chris S, et al. The changing epidemiology of invasive pneumococcal disease at a tertiary children's hospital through the 7-valent pneumococcal conjugate vaccine era: a case for continuous surveillance. Pediatr Infect Dis J 2012; 31:228-34.
12. Centers for Disease Control and Prevention. Pneumonia hospitalizations among young children before and after introduction of pneumococcal conjugate vaccine-United States, 1997-2006. MMWR Morb Mortal Wkly Rep. 2009;58:1-4.
13. Pírez MC, Algorta G, Cedrés A, et al. Impact of universal pneumococcal vaccination on hospitalizations for pneumonia and meningitis in children in Montevideo, Uruguay. Pediatr Infect Dis J 2011; 30:669-74.
14. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int J Infect Dis 2010; 14:e197-209.
15. Pilishvili T, Lexau C, Farley MM, et al; Active Bacterial Core Surveillance/ Emerging Infections Program Network. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis 2010; 201:32-41.
16. Vestrheim DF, Løvoll O, Aaberge IS, et al. Effectiveness of a 2 + 1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 2008; 26:3277-81.
17. Koshy E, Murray J, Bottle A, et al. Impact of the seven-valent pneumococcal conjugate vaccination (PCV7) programme on childhood hospital admissions for bacterial pneumonia and empyema in England: national time-trends study, 1997-2008. Thorax 2010; 65:770-4.
18. Pírez MC, Algorta G, Chamorro F, et al. Changes in hospitalizations for pneumonia after universal vaccination with pneumococcal conjugate vaccines 7/13 valent and Haemophilus influenzae type b conjugate vaccine in a pediatric referral hospital in Uruguay. Pediatr Infect Dis J 2014; 33:753-9.
19. Gutiérrez Brito M, Thompson A, Girgenti D, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in Mexico. Rev Panam Salud Publica 2013; 33:414-21.
20. UNICEF/WHO. Pneumonia: the forgotten killer of children, 2006. Geneva: UNICEF/WHO; 2006. Available at: http://www.who.int/maternal_child_adolescent/documents/9280640489/en/. Accessed October 7, 2013.
21. Afonso ET, Minamisava R, Bierrenbach AL, et al. Effect of 10-valent pneumococcal vaccine on pneumonia among children, Brazil. Emerg Infect Dis 2013; 19:589-97.
22. Bahia L, Toscano CM, Takemoto ML, Araujo DV. Systematic review of pneumococcal disease costs and productivity loss studies in Latin America and the Caribbean. Vaccine 2013; 31 Suppl 3:C33-44.
23. Castañeda E, Agudelo CI, Regueira M, et al; SIREVA II Group. Laboratory-based surveillance of Streptococcus pneumoniae invasive disease in children in 10 Latin American countries: a SIREVA II project, 2000-2005. Pediatr Infect Dis J 2009; 28:e265-70.
24. Martí SG, Colantonio L, Bardach A, et al. A cost-effectiveness analysis of a 10-valent pneumococcal conjugate vaccine in children in six Latin American countries. Cost Eff Resour Alloc 2013; 11:21.
25. Giachetto Larraz G, Telechea Ortiz H, Speranza Mourine N, et al. Costeffectiveness of universal pneumococcal vaccination in Uruguay [in Spanish]. Rev Panam Salud Publica 2010; 28:92-9.
26. Vacunación Universal contra el neumococo lineamientos técnicos. http://www.msal.gov.ar/neumococo/descargas/lineamientos-neumococo-25-11-2011.pdf.
27. Valenzuela MT, O'Loughlin R, De La Hoz F, et al. The burden of pneumococcal disease among Latin American and Caribbean children: review of the evidence. Rev Panam Salud Publica 2009; 25:270-9.